IO Summit 2022 POSTER

Tumor organoid and T cell co-cultures to evaluate CAR-T cell cytotoxicity

With new immunotherapeutics and combination strategies being identified, the number of patients eligible for cancer immunotherapy is expected to expand steadily. However, promising therapeutic developments face hurdles in translating preclinical findings to patients since conventional 2D cancer models fail to capture the high degree of tumor heterogeneity within the clinical population and thereby hold low predictive value.

Download this poster to discover:

• How patient-derived HUB Organoids® represent inter- and intra-tumor heterogeneity and recapitulate patient response
• How expression of check-point molecules such as PD-L1 can be characterized in patient-derived HUB Organoids
• How our organoid and T cell co-culture platform can be used to assess the cytotoxicity of CAR-T cells